These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19729067)

  • 1. Alport syndrome mutations in type IV tropocollagen alter molecular structure and nanomechanical properties.
    Srinivasan M; Uzel SG; Gautieri A; Keten S; Buehler MJ
    J Struct Biol; 2009 Dec; 168(3):503-10. PubMed ID: 19729067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomechanical sequencing of collagen: tropocollagen features heterogeneous elastic properties at the nanoscale.
    Uzel SG; Buehler MJ
    Integr Biol (Camb); 2009 Jul; 1(7):452-9. PubMed ID: 20023755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome.
    Mochizuki T; Lemmink HH; Mariyama M; Antignac C; Gubler MC; Pirson Y; Verellen-Dumoulin C; Chan B; Schröder CH; Smeets HJ
    Nat Genet; 1994 Sep; 8(1):77-81. PubMed ID: 7987396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel Cys1638Tyr NC1 domain substitution in alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities.
    Wilson JC; Yoon HS; Walker RJ; Eccles MR
    Nephrol Dial Transplant; 2007 May; 22(5):1338-46. PubMed ID: 17277342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alport syndrome or progressive hereditary nephritis with hearing loss].
    Gubler MC; Heidet L; Antignac C
    Nephrol Ther; 2007 Jun; 3(3):113-20. PubMed ID: 17540313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.
    Yoshioka K; Hino S; Takemura T; Maki S; Wieslander J; Takekoshi Y; Makino H; Kagawa M; Sado Y; Kashtan CE
    Am J Pathol; 1994 May; 144(5):986-96. PubMed ID: 8178947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome.
    Marcocci E; Uliana V; Bruttini M; Artuso R; Silengo MC; Zerial M; Bergesio F; Amoroso A; Savoldi S; Pennesi M; Giachino D; Rombolà G; Fogazzi GB; Rosatelli C; Martinhago CD; Carmellini M; Mancini R; Di Costanzo G; Longo I; Renieri A; Mari F
    Nephrol Dial Transplant; 2009 May; 24(5):1464-71. PubMed ID: 19129241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Collagen type IV nephropathy: from thin basement membrane nephropathy to Alport syndrome].
    Endreffy E; Ondrik Z; Kemény E; Vas Z; Maróti Z; Lencse G; Bereczki C; Haszon I; Túri S; Iványi B
    Orv Hetil; 2005 Dec; 146(52):2647-53. PubMed ID: 16468607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deformation rate controls elasticity and unfolding pathway of single tropocollagen molecules.
    Gautieri A; Buehler MJ; Redaelli A
    J Mech Behav Biomed Mater; 2009 Apr; 2(2):130-7. PubMed ID: 19627816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families.
    Longo I; Scala E; Mari F; Caselli R; Pescucci C; Mencarelli MA; Speciale C; Giani M; Bresin E; Caringella DA; Borochowitz ZU; Siriwardena K; Winship I; Renieri A; Meloni I
    Nephrol Dial Transplant; 2006 Mar; 21(3):665-71. PubMed ID: 16338941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy.
    Su J; Liu ZH; Zeng CH; Wei-Gong ; Chen HP; Li LS
    Nephrol Dial Transplant; 2006 Jul; 21(7):1838-47. PubMed ID: 16574687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular diagnosis of Alport syndrome.
    Kashtan CE
    Proc Assoc Am Physicians; 1995 Oct; 107(3):306-13. PubMed ID: 8608415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Familial hematuric nephropathies].
    Gubler MC
    Rev Prat; 1997 Sep; 47(14):1545-9. PubMed ID: 9366112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinicopathological study of Alport syndrome and detection of type IV collagen chains in Alport patients.
    Chen N; Pan X; Ren H; Dong D
    Chin Med J (Engl); 1998 Sep; 111(9):797-802. PubMed ID: 11155669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mutations in the COL4A5 gene by SSCP in X-linked Alport syndrome.
    Hertz JM; Juncker I; Persson U; Matthijs G; Schmidtke J; Petersen MB; Kjeldsen M; Gregersen N
    Hum Mutat; 2001 Aug; 18(2):141-8. PubMed ID: 11462238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign familial hematuria due to mutation of the type IV collagen alpha4 gene.
    Lemmink HH; Nillesen WN; Mochizuki T; Schröder CH; Brunner HG; van Oost BA; Monnens LA; Smeets HJ
    J Clin Invest; 1996 Sep; 98(5):1114-8. PubMed ID: 8787673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inherited diseases of the glomerular basement membrane.
    Gubler MC
    Nat Clin Pract Nephrol; 2008 Jan; 4(1):24-37. PubMed ID: 18094725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of frailty models in genetic studies: application to the relationship between end-stage renal failure and mutation type in Alport syndrome. European Community Alport Syndrome Concerted Action Group (ECASCA).
    Albert I; Jais JP
    J Epidemiol Biostat; 2000; 5(3):169-75. PubMed ID: 11051113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glycine substitutions on alpha5(IV) chain structure and structure-phenotype correlations in Alport syndrome.
    Wang YF; Ding J; Wang F; Bu DF
    Biochem Biophys Res Commun; 2004 Apr; 316(4):1143-9. PubMed ID: 15044104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.